Welcome to our dedicated page for Pure Bioscience SEC filings (Ticker: PURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PURE Bioscience filings document regulatory disclosures for an operating company commercializing patented silver dihydrogen citrate antimicrobial products. Current reports furnish fiscal operating results, press releases, and business updates tied to product sales, research and development, working capital, and administrative expenses.
The filing record also covers capital-structure and governance matters, including a private placement of common stock to accredited investors, annual meeting votes, director elections, auditor ratification, executive compensation proposals, and officer appointments. Proxy materials describe stockholder voting procedures, board matters, compensation items, and annual reporting materials.
PURE Bioscience, Inc. filed its annual report for the year ended July 31, 2025. The company reported net product sales of $2.20 million, up from $1.96 million in 2024, and a net loss of $2.4 million versus a $3.4 million loss last year. Cash was $334,000 as of July 31, 2025, and auditors expressed substantial doubt about the company’s ability to continue as a going concern.
The business focuses on proprietary silver dihydrogen citrate (SDC) antimicrobial products, including PURE Hard Surface (EPA-registered) and PURE Control (FDA Food Contact Notifications for poultry and produce). Customer concentration remains notable; the largest customer represented 18% of net product sales in 2025. As of October 29, 2025, there were 111,886,473 shares outstanding. The company completed a private placement of convertible debt with $2.0 million in net proceeds during fiscal 2025 and indicates the need for additional capital to fund operations.
PURE continues to pursue food-safety markets through distributors and partnerships while navigating extensive regulatory requirements from the EPA, FDA, USDA and foreign authorities.
PURE Bioscience (PURE) furnished an 8‑K under Item 2.02 announcing a press release with financial results for the fiscal year ended July 31, 2025. The press release is attached as Exhibit 99.1. The company states the information is being furnished, not filed, and will not be incorporated by reference into other SEC filings.